why choose us

First received: November 22, 2022

Clinical Trial: Intravesical Gemcitabine in Patients With NMIBC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Urinary Bladder Cancer

Study Type: INTERVENTIONAL


Official Title: Phase II Trial of Intravesical Gemcitabine in Patients With Nonmuscle Invasive Bladder Cancer With or Without Prior Bacillus Calmette-Guérin Therapy

Brief Summary: Intravesical immunotherapy or chemotherapy for non-muscle invasive bladder cancer is a well-established treatment for preventing or delaying tumor recurrence after bladder tumor resection.For high-risk non-muscle invasive bladder cancer, immunotherapy in the form of intravesical Bacillus Calmette-Guérin (BCG) can be effective as first-line, nevertheless, the response rate to BCG is suboptimal with many patients failing treatment.Following BCG-failure, however, very few effective therapeutic options exist besides…

Read more